2023
Aging gene signature of memory CD8+ T cells is associated with neurocognitive functioning in Alzheimer’s disease
Young J, Park H, Kim M, Par-Young J, Bartlett H, Kim H, Unlu S, Osmani L, Shin M, Bucala R, van Dyck C, Allore H, Mecca A, You S, Kang I. Aging gene signature of memory CD8+ T cells is associated with neurocognitive functioning in Alzheimer’s disease. Immunity & Ageing 2023, 20: 71. PMID: 38042785, PMCID: PMC10693128, DOI: 10.1186/s12979-023-00396-y.Peer-Reviewed Original ResearchPeripheral bloodT cellsAlzheimer's diseaseEM CD8Memory CD8Gene signatureAge-related immune changesIL-7 receptor alphaEffector memory CD8Strong risk factorT cell expansionAD genesAge-associated expansionImmune changesRisk factorsCD8Dementia patientsIL-7RNeuropsychological testingReceptor alphaNeurocognitive functionRT-qPCR resultsDisease severityPatientsNormal persons
2020
Breast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes
Wang L, Simons D, Lu X, Tu T, Avalos C, Chang A, Dirbas F, Yim J, Waisman J, Lee P. Breast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes. EBioMedicine 2020, 52: 102631. PMID: 31981982, PMCID: PMC6992943, DOI: 10.1016/j.ebiom.2020.102631.Peer-Reviewed Original ResearchConceptsSystemic immune changesPeripheral blood monocytesBreast Cancer Research FoundationBreast Cancer Research ProgramBC patientsImmune changesBlood monocytesPeripheral bloodImmune cellsNon-metastatic BC patientsPeripheral blood immune cellsPeripheral blood T cellsCancer patients' peripheral bloodBlood immune cellsBreast cancer patientsOverall immune statusBlood T cellsPatients' peripheral bloodTumor-infiltrating macrophagesDefense Breast Cancer Research ProgramCancer Research ProgramCancer Research FoundationConcurrent cytokineLocalized diseaseImmune status
2018
Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial
Pelekanou V, Barlow WE, Nahleh Z, Wasserman B, Lo YC, von Wahlde MK, Hayes D, Hortobagyi GN, Gralow J, Tripathy D, Porter P, Szekely B, Hatzis C, Rimm DL, Pusztai L. Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial. Molecular Cancer Therapeutics 2018, 17: molcanther.1005.2017. PMID: 29588392, PMCID: PMC6548451, DOI: 10.1158/1535-7163.mct-17-1005.Peer-Reviewed Original ResearchConceptsPD-L1 expressionPathologic complete responseTIL countPosttreatment tissuePD-L1Estrogen receptorImmune checkpoint inhibitor therapyPD-L1 positivity rateTumor-infiltrating lymphocyte countsDoxorubicin/cyclophosphamideCheckpoint inhibitor therapyPD-L1 levelsMol Cancer TherNab-paclitaxelLymphocyte countResidual cancerComplete responseER statusImmune changesInhibitor therapyCox regressionPatient populationControl armClinical trialsPositivity rate
2017
Host-related immunodeficiency in the development of multiple myeloma
Dosani T, Mailankody S, Korde N, Manasanch E, Bhutani M, Tageja N, Roschewski M, Kwok M, Kazandjian D, Costello R, Burton D, Zhang Y, Liewehr D, Steinberg SM, Maric I, Landgren O. Host-related immunodeficiency in the development of multiple myeloma. Leukemia & Lymphoma 2017, 59: 1127-1132. PMID: 28792255, PMCID: PMC6750254, DOI: 10.1080/10428194.2017.1361026.Peer-Reviewed Original ResearchConceptsMultiple myelomaLymphocyte subsetsCD57- subsetImmune biomarkersDevelopment of MMMyeloma precursor diseaseNK cell proportionNovel immune biomarkersProgression of SMMMultiparametric flow cytometrySMM patientsImmune changesImmune patternsClinical guidancePrecursor diseaseCell proportionFlow cytometryMGUSPotential markerImmunodeficiencySequential changesMyelomaPatientsPrecursor conditionsProgression
2015
Paradoxical changes in innate immunity in aging: recent progress and new directions
Montgomery RR, Shaw AC. Paradoxical changes in innate immunity in aging: recent progress and new directions. Journal Of Leukocyte Biology 2015, 98: 937-943. PMID: 26188078, PMCID: PMC4661037, DOI: 10.1189/jlb.5mr0315-104r.Peer-Reviewed Original ResearchConceptsImmune responseInnate immune changesInnate immune responseCytokine levelsInappropriate elevationImmune changesNaïve cell populationT cellsAdaptive immunityViral infectionParadoxical increaseInnate immunityMultiple cell typesParadoxical changesCell populationsActivation stateImmunityCell typesSevere consequencesResponseTissue contextImmunosenescenceVaccinationPopulationInfection
2012
Evidence for an association between tumor necrosis factor-alpha levels and lithium response
Guloksuz S, Altinbas K, Cetin E, Kenis G, Gazioglu S, Deniz G, Oral E, van Os J. Evidence for an association between tumor necrosis factor-alpha levels and lithium response. Journal Of Affective Disorders 2012, 143: 148-152. PMID: 22749155, DOI: 10.1016/j.jad.2012.04.044.Peer-Reviewed Original ResearchConceptsTNF-α levelsBipolar patientsLithium responsePartial responseTumor necrosis factor-alpha levelsBipolar disorderTreatment-resistant bipolar patientsNecrosis factor-alpha levelsRole of inflammationPotential pathophysiological mechanismsAdditional inflammatory markersAssessment of responseGood responseEnzyme-linked immunosorbentEuthymic bipolar patientsImmune imbalanceImmune alterationsInflammatory markersImmune changesPathophysiological mechanismsPotential confoundersLithium therapyNatural coursePoor responseTreatment response
2009
Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice
Xiao X, Ma B, Dong B, Zhao P, Tai N, Chen L, Wong FS, Wen L. Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice. Journal Of Autoimmunity 2009, 32: 85-93. PMID: 19200691, DOI: 10.1016/j.jaut.2008.12.003.Peer-Reviewed Original ResearchConceptsDiabetic NOD miceNOD miceDiabetic nephropathyDiabetic miceNon-diabetic NOD miceNon-obese diabetic (NOD) miceDuration of diabetesUrinary albumin excretionAdditional therapeutic targetsHumoral immune responseAlbumin excretionAutoimmune diabetesDendritic cellsDiabetes onsetImmune changesKidney weightIgG depositsHumoral immunityT cellsImmune responseNephropathyComplement C3Therapeutic targetB cellsImmune system
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply